Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Increased expression of ATP12A proton pump in cystic fibrosis airways
Paolo Scudieri, … , Gilles Crambert, Luis J.V. Galietta
Paolo Scudieri, … , Gilles Crambert, Luis J.V. Galietta
Published October 18, 2018
Citation Information: JCI Insight. 2018;3(20):e123616. https://doi.org/10.1172/jci.insight.123616.
View: Text | PDF
Research Article Pulmonology

Increased expression of ATP12A proton pump in cystic fibrosis airways

  • Text
  • PDF
Abstract

Proton secretion mediated by ATP12A protein on the surface of the airway epithelium may contribute to cystic fibrosis (CF) lung disease by favoring bacterial infection and airway obstruction. We studied ATP12A in fresh bronchial samples and in cultured epithelial cells. In vivo, ATP12A expression was found almost exclusively at the apical side of nonciliated cells of airway epithelium and in submucosal glands, with much higher expression in CF samples. This could be due to bacterial infection and inflammation, since treating cultured cells with bacterial supernatants or with IL-4 (a cytokine that induces goblet cell hyperplasia) increased the expression of ATP12A in nonciliated cells. This observation was associated with upregulation and translocation of ATP1B1 protein from the basal to apical epithelial side, where it colocalizes with ATP12A. ATP12A function was evaluated by measuring the pH of the apical fluid in cultured epithelia. Under resting conditions, CF epithelia showed more acidic values. This abnormality was minimized by inhibiting ATP12A with ouabain. Following treatment with IL-4, ATP12A function was markedly increased, as indicated by strong acidification occurring under bicarbonate-free conditions. Our study reveals potentially novel aspects of ATP12A and remarks its importance as a possible therapeutic target in CF and other respiratory diseases.

Authors

Paolo Scudieri, Ilaria Musante, Emanuela Caci, Arianna Venturini, Patrizia Morelli, Christine Walter, Davide Tosi, Alessandro Palleschi, Pablo Martin-Vasallo, Isabelle Sermet-Gaudelus, Gabrielle Planelles, Gilles Crambert, Luis J.V. Galietta

×

Figure 8

Apical fluid pH measurement.

Options: View larger image (or click on image) Download as PowerPoint
Apical fluid pH measurement.
(A) Dot plot (single values and median) sho...
(A) Dot plot (single values and median) showing apical fluid pH measured in cultured CF and non-CF bronchial epithelia treated with/without IL-4 for 72 hours (***P < 0.001; data collected from 6 CF and 6 non-CF bronchial cell preparations; n = 15–18 separate epithelia for each condition). (B and C) Dot plots (single values and median) showing apical fluid pH measured in non-CF (B) and CF (C) bronchial epithelia treated with/without IL-4 for 72 hours. Before pH measurement, cells were incubated for 3 hours with a basolateral medium containing HCO3– or HEPES and with 75 μl of a modified PBS solution on the apical side. Where indicated, this solution also contained 200 μM ouabain (**P < 0.01, ***P < 0.001; data collected from 4 Îseparate CF and non-CF bronchial cell preparations). (D) The data reported in B and C are replotted to directly compare side-by-side CF and non-CF data for each condition. The dashed line in each panel indicates the initial pH of the saline solution.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts